News

Pill version of Novo Nordisk’s Wegovy approved, possibly widening access

Regulatory 72/100How we got 72/100Source tierEstablished referenceTier ceiling72/100Independent sourcesnot recordedPublished score72/100Scored at the ceiling for a established reference source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

The FDA has approved an oral version of Novo Nordisk’s Wegovy for weight loss and cardiovascular risk reduction. Clinical trials showed the pill achieves similar efficacy to the injectable form, with patients losing approximately 14% of their body weight. This approval marks the first time a GLP-1 pill has been cleared for obesity, potentially increasing access for those averse to injections.

Related peptides

SemaglutideTirzepatideGLP-1GLP-1 receptor agonistGLP-1R
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.